The introduction of fentanyl, a potent synthetic opioid, into the U.S. drug supply has remade the landscape for health and recovery. This includes changing norms around the use of methadone, a common treatment option for opioid use disorder.
A new paper published in Health and Quality of Life Outcomes identified a positive association between higher methadone dosage and patient quality of life.
This work was led by Shadi Izadidehkordi, postdoctoral research associate, and Michael Copenhaver, professor of health promotion, in the Department of Allied Health Sciences in the College of Agriculture, Health and Natural Resources (CAHNR).
Methadone has been used to treat opioid use disorder for decades. The drug works by occupying the same receptors as opioids like fentanyl or heroin. It reduces withdrawal symptoms and cravings and makes the highs and crashes experienced with illicit opioids less intense.
“Like fentanyl, methadone is a synthetic opioid,” Izadidehkordi says. “It’s sitting on the same receptors. But it lowers the intensity of cravings and withdrawals. When those symptoms are controlled with a maintained methadone dose, it brings some level of stability back into their lives, preventing their addiction from disrupting their day-to-day life.
Patients need to be present in a drug treatment program to receive their daily methadone dose. Methadone clinics start patients at a low dose that does not have a pharmacologically significant effect before eventually ramping up to a standard long-term dose. However, the final dose for each patient is decided based on clinical symptoms and tolerance to opioids. Therefore, methadone dosing guidelines are not fixed and there is no universally accepted standard for what this final dose should be.
If a patient is on too low of a dose, they can “shoot over” methadone and still use other opioids.
“If they aren’t on a high enough dose, they are able, to some extent, to use drugs on top of the dose that they’re on,” Copenhaver says. “That’s why it’s important that we get them on a dose that is sufficient to keep them stabilized over a long period of time.”
Because fentanyl produces higher cravings, as well as a greater overdose risk, some clinics have already been administering higher doses of methadone to be able to control fentanyl-related symptoms.
“This is a whole different era of developing the proper dosage, and some clinics are behind in making that adjustment,” Copenhaver says.
In this study, Izadidehkordi and Copenhaver looked at data from patients receiving methadone treatment at a methadone clinic in New Haven. They administered a 36 item questionnaire to patients which measured quality of life using a scale called SF-6D. This measure focuses on six domains of quality of life: mental health, physical functioning, role limitations, social functioning, pain and vitality.
“SF-6D is superior to other quality of life assessments because it focuses more strongly on the mental health aspect,” Izadidehkordi says. “We know the mental health crisis and the opioid overdose crisis have become overlapping conditions.”
SF-6D uses an algorithm to score each patient’s responses on a utility scale of zero to one, with one representing perfect health.
The researchers found that patients on the two highest levels of methadone dose (90-120 mg and above 120 mg) had higher quality of life scores than those on lower doses.
Thanks to their novel methodology, the researchers were able to isolate the impact of methadone dose on quality of life.
“The methadone dose is not the main underlying factor impacting quality of life,” Izadidehkordi says. “But the positive effects of increased doses were significant.”
While the improvement may have been modest, changing a patient’s methadone dose is something clinics can directly control. Successfully stabilizing a patient can also help retain them in treatment.
“Sometimes variables that are important are factors you have no control over,” Copenhaver says. “[This is] good for individual and public health and it’s something a clinic can directly control.”
Increasing methadone dose is a relatively cheap way to accrue significant benefits by keeping patients retained in treatment, thus reducing the overall burden on the healthcare system.
“If you can increase the dose, it’s not going to cost a lot of money,” Izadidehkordi says. “But it will bring positive health outcomes that, in the end, translate to a cost-effective measure, reducing the burden of opioid use disorder
The researchers are now collecting more data to determine how methadone dose impacts quality of life for people in their first year of methadone treatment.
“These data came from a trial with people who were fairly well-established in treatment,” Copenhaver says. “We now are doing a study with people who are new to treatment – a really unstable population. We’ll be able to make those comparisons and see if this is maybe a shortcut to keeping them safer and retained in treatment.”
This work relates to CAHNR’s Strategic Vision area focused on Enhancing Health and Well-Being Locally, Nationally, and Globally.
Follow UConn CAHNR on social media